Trial Profile

A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vadastuximab talirine (Primary) ; Cytarabine; Daunorubicin
Indications Acute myeloid leukaemia
Focus Adverse reactions

Most Recent Events

08 May 2018 Status changed from suspended to completed.
25 Jun 2017 Cohort results from this trial presented at the 22nd Congress of the European Haematology Association
19 Jun 2017 According to a company media release, Seattle Genetics is suspending patient enrollment and treatment in all of its vadastuximab talirine clinical trials based on unfavourable results obtained in the phase III CASCADE trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com